GCS001c

About Glen Clova Scientific

Glen Clova Scientific is a private, preclinical-stage biotech leveraging a proprietary Virus-Like Particle (VLP) platform to develop therapeutic vaccines. Its technology is designed to induce natural antibody responses with drastically lower dosing requirements and cost of goods compared to conventional biologics, targeting improved accessibility in both human and veterinary medicine. The lead program, GCS001 for senile pruritus, is slated to enter clinical trials in 2026. The company operates from Dundee, UK, and appears to be pre-revenue, focusing on R&D and potential partnerships.

Therapeutic Areas